Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (HIMS)
NYSE:HIMS
Hims & Hers Health (HIMS) Stock Price & Analysis
1,809 Followers
HIMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.65 - $25.74
Previous Close$19.42
Volume15.01M
Average Volume (3M)10.84M
Market Cap
$4.17B
Enterprise Value$3.96B
Total Cash (Recent Filing)$221.00M
Total Debt (Recent Filing)$9.95M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Aug 05, 2024EPS Estimate
$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding214,786,086
10 Day Avg. Volume11,150,336
30 Day Avg. Volume10,840,198
Standard Deviation0.20
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)22.17
Price to Sales (P/S)18.54
Price to Cash Flow (P/CF)54.10
P/FCF Ratio35.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.54
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda214.67
Forecast
1Y Price Target
$21.73Price Target Upside11.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Hims & Hers Health News
Bulls Say, Bears Say
Bulls Say
Brand StrengthAnalyst is optimistic about the early pace of HIMS’ roll-out and the company’s diversified product offering and strong brand.
Revenue GrowthGLP-1 launch drives reacceleration of revenue growth.
Sales GrowthObserved sales growth accelerated for the third consecutive month, up 8pts from May.
Bears Say
Earnings UncertaintySignificant uncertainty exists around the durability of the earnings stream once branded GLP-1s come off the shortage list.
Market ValueWith the stock up 20% since the announcement, HIMS has effectively added ~$760M of enterprise value on limited new information, leaving little room for upside.
Regulatory RisksThe FDA is increasing scrutiny of compounded GLP-1s, and major pharmaceutical companies have been taking legal action against what they consider counterfeit drugs.
---
Ownership Overview
37.44% Insiders
16.14% Mutual Funds
14.38% Other Institutional Investors
32.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
The estimated number of people who visited one or more of the websites owned by Hims & Hers Health
Desktop Users
Mobile Users
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $5.65 and its highest was $25.74 in the past 12 months.
What is Hims & Hers Health’s market cap?
Currently, no data Available
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on May 06, 2024. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.04.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is $0.04.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 206,408,460 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of $0.05 in its last earnings report, beating expectations of $0.01. Following the earnings report the stock price went up 6.009%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Among the largest hedge funds holding Hims & Hers Health’s share is Farallon Capital Management, L.L.C.. It holds Hims & Hers Health’s shares valued at 26M.
---
Hims & Hers Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.73 (11.89% Upside)
$21.73 (11.89% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.44%
12-Months-Change
Fundamentals
Return on Equity
-0.72%
Trailing 12-Months
Asset Growth
19.08%
Trailing 12-Months
Company Description
Hims & Hers Health
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
---
HIMS Company Deck
---
HIMS Earnings Call
Q1 2024
0:00 / 0:00
---
HIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
---
HIMS Stock 12 Month Forecast
Average Price Target
$21.73
▲(11.89% Upside)
Technical Analysis
Best Analysts Covering HIMS
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+92.16%
reiterated a buy rating 5 months ago
Copying Jack Wallace's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +92.16% per trade.
---